Protein kinase inhibitor

Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer

Retrieved on: 
Monday, October 21, 2019

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive topline results from the HER2CLIMB trial, a randomized, double-blind, placebo-controlled, active comparator pivotal trial evaluating tucatinib.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive topline results from the HER2CLIMB trial, a randomized, double-blind, placebo-controlled, active comparator pivotal trial evaluating tucatinib.
  • The trial compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.
  • Seattle Genetics management will host a conference call and webcast to discuss topline results from the HER2CLIMB clinical trial of tucatinib.
  • Tucatinib, a small molecule tyrosine kinase inhibitor, is in clinical trials for HER2-positive metastatic breast cancer and metastatic colorectal cancer.

Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 16, 2019

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26-30, 2019 in Boston, Massachusetts.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26-30, 2019 in Boston, Massachusetts.
  • The details for the poster presentation are as follows:
    Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers.
  • Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer.
  • The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib.

Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma

Retrieved on: 
Thursday, October 3, 2019

CANTATA is a global, randomized double-blind clinical trial of the glutaminase inhibitor telaglenastat (CB-839) combined with cabozantinib, a standard of care, in patients with advanced or metastatic renal cell carcinoma (RCC) who have received one or two prior treatments.

Key Points: 
  • CANTATA is a global, randomized double-blind clinical trial of the glutaminase inhibitor telaglenastat (CB-839) combined with cabozantinib, a standard of care, in patients with advanced or metastatic renal cell carcinoma (RCC) who have received one or two prior treatments.
  • Exelixis, Inc. is providing cabozantinib for the trial through a material supply agreement with Calithera.
  • Despite the introduction of new therapies, the treatment of patients with advanced renal cell carcinoma who have progressed on initial treatments remains a critical unmet need.
  • Calithera plans to report top-line efficacy and safety data from the trial in the second half of 2020.

Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer

Retrieved on: 
Tuesday, September 10, 2019

The late-breaking data were featured today in a Mini Oral Session at the IASLC 2019 World Conference on Lung Cancer (#WCLC19) in Barcelona, Spain (# MA21.06 , Abstract #1720).

Key Points: 
  • The late-breaking data were featured today in a Mini Oral Session at the IASLC 2019 World Conference on Lung Cancer (#WCLC19) in Barcelona, Spain (# MA21.06 , Abstract #1720).
  • All 30 patients in the trial had received prior treatment with an EGFR tyrosine kinase inhibitor (TKI) including 28 (93 percent) with osimertinib.
  • At the time of data cut-off on May 3, 2019, a total of 17 patients remained on treatment.
  • The global, phase 1, open label, two-part study is enrolling patients with metastatic or unresectable EGFR mutated NSCLC whose disease has progressed while taking an EGFR TKI.

Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer

Retrieved on: 
Tuesday, September 10, 2019

The late-breaking data were featured today in a Mini Oral Session at the IASLC 2019 World Conference on Lung Cancer (#WCLC19) in Barcelona, Spain (# MA21.06 , Abstract #1720).

Key Points: 
  • The late-breaking data were featured today in a Mini Oral Session at the IASLC 2019 World Conference on Lung Cancer (#WCLC19) in Barcelona, Spain (# MA21.06 , Abstract #1720).
  • All 30 patients in the trial had received prior treatment with an EGFR tyrosine kinase inhibitor (TKI) including 28 (93 percent) with osimertinib.
  • At the time of data cut-off on May 3, 2019, a total of 17 patients remained on treatment.
  • The global, phase 1, open label, two-part study is enrolling patients with metastatic or unresectable EGFR mutated NSCLC whose disease has progressed while taking an EGFR TKI.

Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer

Retrieved on: 
Wednesday, September 4, 2019

The approval of NERLYNX in Argentina follows marketing authorizations in the United States, Europe, Australia and Canada.

Key Points: 
  • The approval of NERLYNX in Argentina follows marketing authorizations in the United States, Europe, Australia and Canada.
  • HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death.
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
  • Indication
    INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

Selvita to Present at Upcoming Conferences in September

Retrieved on: 
Tuesday, September 3, 2019

Pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, immuno-oncology and cancer metabolism targets.

Key Points: 
  • Pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, immuno-oncology and cancer metabolism targets.
  • SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in Phase 1/2 clinical development for the treatment of acute myeloid leukemia.
  • Selvita is headquartered in Krakow, Poland, with offices in the U.S. and U.K. Ardigen, a provider of precision medicine and artificial intelligence services, and NodThera, a company developing a new class of medicines to treat chronic inflammation, were launched by Selvita.
  • In March 2019, Selvita announced the intent to split its oncology development and research services divisions into separate companies.

A New Class of Kinase Inhibitors for the Treatment of Cardiovascular Disease

Retrieved on: 
Monday, August 12, 2019

WASHINGTON, Aug. 12, 2019 /PRNewswire/ -- An article published in Experimental Biology and Medicine (Volume 244, Issue 11, August, 2019) ( https://journals.sagepub.com/doi/pdf/10.1177/1535370219849581 ) describes a new class of kinase inhibitors.

Key Points: 
  • WASHINGTON, Aug. 12, 2019 /PRNewswire/ -- An article published in Experimental Biology and Medicine (Volume 244, Issue 11, August, 2019) ( https://journals.sagepub.com/doi/pdf/10.1177/1535370219849581 ) describes a new class of kinase inhibitors.
  • High blood pressure, or hypertension, is the principal cause of cardiovascular disease and afflicts 1 out of every 3 adults.
  • Rho-activated kinases (ROCKs) are important signaling components in smooth muscle cells, and attenuation of ROCK signaling reduces disease progression in many pre-clinical models of cardiovascular disease.
  • One strategy for increasing specificity is developing inhibitors that target divergent regulatory domains of the kinase instead of the highly conserved ATP-binding site.

TURALIO™ (pexidartinib), FDA Approved Treatment of TGCT, Available at Biologics by McKesson

Retrieved on: 
Wednesday, August 7, 2019

TURALIO, a first-in-class oral tyrosine kinase inhibitor for TGCT, was approved by the FDA on August 2, 2019.

Key Points: 
  • TURALIO, a first-in-class oral tyrosine kinase inhibitor for TGCT, was approved by the FDA on August 2, 2019.
  • For these patients, treatment options are limited because there are no approved systemic therapies for the disease.
  • TURALIO is approved with a Boxed Warning for the risk of serious and potentially fatal liver injury.
  • Across 768 patients who received TURALIO in clinical trials, there were two irreversible cases of cholestatic liver injury.

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Outlook 2019-2023 with Bayer, Gilead Sciences, Novartis, TG Therapeutics, and Verastem Leading the Competition - ResearchAndMarkets.com

Retrieved on: 
Monday, July 29, 2019

The "Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • Although many approved therapies are available for various types of blood cancer, the market still witnesses a huge unmet need.
  • The phosphoinositide 3-kinase inhibitors market analysis considers sales from chronic lymphocytic leukaemia (CLL), follicular lymphoma (FL), and other indications.
  • With the presence of few major players, the global phosphoinositide 3-kinase inhibitors market is concentrated.